First Tracks Biotherapeutics, I (TRAX) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.88

Estimate

-$0.88

Surprise

+0.1%

Score today

5.7/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

First Tracks Biotherapeutics, I (TRAX) reported adjusted EPS of -$0.88, in line with the -$0.88 estimate.

• Guggenheim Maintains Buy Rating and Raises Price Target for First Tracks Biotherapeutics — fiscal.ai, 2026-11-04
• Guggenheim Maintains Buy on First Tracks, Raises Price Target to $110 — benzinga, 2026-11-04
• Analyst Price Target for First Tracks Biotherapeutics Raised to $75 — fiscal.ai, 2026-11-04

TrendMatrix currently rates TRAX Sell at 5.7/10; no pre/post engine snapshot brackets this report.

0 of the last 3 quarters beat the estimate; this quarter's +0.1% surprise compares with a -9.1% four-quarter average. Next scheduled report: 2027-02-23.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$49.04

Price target

$64.53

Stop

$45.61

Upside to target

+31.6%

Reward-to-risk

2.1:1

Model outputs from TrendMatrix’s engine as of 2026-11-05 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$2.06B

P/E (fwd)

-13.6

52-week range

$14.72–$50.16

Off 52-week high

2.2%

RSI (14)

85

Volume vs avg

0.79×

Score today

5.7/10